Dr. Reddy's granted FDA nod for first generic targeting Gilead’s Yeztugo

Dr. Reddy's Laboratories (RDY) stock gains as the firm wins FDA nod for a generic targeting Yeztugo, an HIV PrEP therapy developed by Gilead (GILD). Read more here.

CryptoAlerta — análise de criptomoedas e mercado em tempo real